Mein Warenkorb

GFR alpha-1

GFR alpha-1 Molekülinformation

Englischer NameGlial cell line-derived neurotrophic factor receptorsAnzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel3Target-AliasGlial Cell Line-Derived Neurotrophic Factor Receptors
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical
Englischer NameGlial cell line-derived neurotrophic factor receptors
Target-AliasGlial Cell Line-Derived Neurotrophic Factor Receptors
Anzahl der inverkehr gebrachten Arzneimittel0
Anzahl der klinischen Arzneimittel3
Höchste Forschungs- und EntwicklungsphasePhase 2 Clinical

GFR alpha-1 Produktliste

  • Attribut

    Protein (1)

  • Produktbibliothek

    Online (1)

  • Spezies

    Human (1)

  • Etikett

    His Tag (1)

  • Marker

    Unconjugated (1)

ProduktnummerSpeziesExpressionssystemProduktbeschreibungProteinstrukturReinheitEigenschaftenVorbestellen/Bestellen
GF1-H5224
Human
HEK293
Human GFR alpha-1 Protein, His Tag
In den Warenkorb legen
Gesamtmenge1
  • 1

GFR alpha-1 Molekülhintergrund

GDNF family receptor alpha-1 (GFRA1) is also known as RET ligand 1 (RETL1), TGF-beta-related neurotrophic factor receptor 1 (TRNR1), is a novel glycosylphosphatidylinositol (GPI)-linked cell surface receptor, and belongs to the glial cell line-derived neurotrophic factor (GDNF) receptor subfamily. The GDNF family ligands comprises GDNF, Neurturin (NTN), Artemin, and Persephin. GDNF and NTN are two structurally related, potent neurotrophic factors that play key roles in the control of neuron survival and differentiation. GFRA1 mediates the association with and activation of the RET tyrosine kinase receptor (RTK), and subsequently initiates the RET signaling pathway. GFR alpha-mediated signaling plays an important role in the survival, differentiation, and migration of central and peripheral neurons, and is essential for the development of kidneys and the enteric nervous system, as well as the inflammatory response in some carciniomas.

GFR alpha-1 Molekülalias

GFRA1,GDNFRA,RETL1,TRNR1,GDNFR,GFR-ALPHA-1,RET1L

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
KLS-2031KLS-2031Phase 2 ClinicalKolon Life Science. IncNeuralgia; Radiculopathy
Details
NGM-386NGM-386Phase 1 ClinicalNGM Biopharmaceuticals IncObesity
Details
NGM-395NGM-395Phase 1 ClinicalNGM Biopharmaceuticals IncMetabolic Dysfunction-Associated Steatotic Liver Disease; Obesity
Details
  • Molekülinformation
  • Produktliste
  • Klinische Arzneimittelinformation
Kontaktieren Sie uns